Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Alexis Ogdie¹, Kathleen Bush¹, Michael George¹, Mitesh Patel¹, William Nowell², Kelly Gavigan³, Jeffrey Curtis⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, New York City, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
Abstract Number: 0901 • ACR Convergence 2020
Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence
Robert Moots¹, Andy Cross², Helen Wright², Steven Edwards², Nicola Goodson³, Jenny Hawkes³, Ayren Mediana¹ and Helen Frankland¹, ¹Liverpool University Hospitals, Liverpool, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³University of Liverpool, Liverpool
Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA). …
Abstract Number: 1314 • ACR Convergence 2020
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Jessica Walsh¹, Kaleb Michaud², Elizabeth Holdsworth³, Steven Peterson⁴, Nicola Booth³, Sophie Meakin³, Soumya Chakravarty⁵, James Piercy³ and Alexis Ogdie⁶, ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Nebraska Medical Center, Omaha, NE, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Fatigue is an important aspect of PsA for patients. Understanding the impact of fatigue on patient reported outcomes is important for effective management of…
Abstract Number: 1351 • ACR Convergence 2020
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
Lars Erik Kristensen¹, Masato Okada², William Tillett³, Soyi Liu-Leage⁴, Celine El Baou⁵, Andrew Bradley⁵, Gabriella Meszaros⁴ and Kurt de Vlam⁶, ¹The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ²St. Luke's International University, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ³Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁶Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium
Background/Purpose: Ixekizumab (IXE), a selective interleukin-17A antagonist, is approved for the treatment of active PsA, moderate-to-severe psoriasis (PsO), and radiographic/non-radiographic axial SpA in adults. The…
Abstract Number: 1520 • ACR Convergence 2020
Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts
Clare Cunningham¹, Sharon Ansboro¹, Sarah Wade¹, Candice Low², Ronan Mullan³, Douglas Veale⁴ and Ursula Fearon⁵, ¹Trinity College Dublin, Dublin, Ireland, ²EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ³Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁵Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The synovial inflammation observed in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) is characterised by synovial fibroblast hyperplasia, leukocyte infiltration, neoangiogenesis and hypoxia. These…
Abstract Number: 1981 • ACR Convergence 2020
Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
Thomas Davergne¹, Rawdha Tekaya², Camille Deprouw³, Anne Tournadre⁴, Stéphane Mitrovic⁵, Adeline Ruyssen-Witrand⁶, Christophe Hudry⁷, Sabrina Dadoun⁸, Jérôme Avouac⁹, Kate Betteridge¹⁰, Bruno Fautrel¹¹ and Laure Gossec¹², ¹Sorbonne University, INSERM, IPLES, Paris, France, ²Hôpital Charles Nicolle, Rheumatology department, Tunis, Tunisia, Tunis, Tunisia, ³1. AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, France, Paris, France, ⁴CHU Gabriel Montpied, Clermont-Ferrand, ⁵Institut Mutualiste Montsouris, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ⁶Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁷CeSOA, MGEN, Paris, France, Paris, Ile-de-France, France, ⁸Medical centre, Paris, France, paris, Ile-de-France, France, ⁹Cochin hospital, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ¹⁰Patient research partner, UK, london, England, United Kingdom, ¹¹Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹²Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic…
Abstract Number: 123 • 2020 Pediatric Rheumatology Symposium
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ⁸, Pamela Weiss ⁹ and Timothy Beukelman ⁷ for the CARRA investigators, ¹University of Alberta, Edmonton, Canada, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Duke Children's Hospital & Health Center, Durham, North Carolina, ⁵Amgen, Long Beach, ⁶Florida, Gainesville, ⁷University of Alabama at Birmingham, Birmingham, ⁸Amgen, Inc, San Francisco, ⁹Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: 582 • 2019 ACR/ARP Annual Meeting
Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Einer Sanchez Prado¹, Alvaro Ruta ², Jessica Torres Chichande ², Santiago Ruta ³, Sebastian Magri ², Facundo Salvatori ² and Rodrigo Garcia Salinas ², ¹Hospital Italiano de La Plata, La Plata, ²Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ³Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina
Background/Purpose: In our region, the lack of knowledge, timely referral and access to laboratory tests and images are the main causes in the diagnostic delay…
Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Klaus Krüger¹, Sven Remstedt ², Astrid Thiele ³ and Ines Klaudius ⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…
Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1534 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Laura Coates¹, Philip Mease ², Dafna Gladman ³, Filip Van den Bosch ⁴, Anna Rychlewska-Hanczewska ⁵, Chantal Tasset ⁶, Luc Meuleners ⁶, Mona Trivedi ⁷, Jingjing Gao ⁷, Robin Besuyen ⁶ and Philip Helliwell ⁸, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Ghent University Hospital, Ghent, Belgium, ⁵5ai centrum medyczne sp. z o.o. sp.k., Poznan, Poland, Poznan, Poland, ⁶Galapagos NV, Mechelen, Belgium, ⁷Gilead Sciences Inc, Foster City, United States of America, Foster City, CA, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for psoriatic arthritis (PsA). Efficacy and safety of FIL in…
Abstract Number: 2246 • 2019 ACR/ARP Annual Meeting
Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Kaleb Michaud ¹, Evo Alemao ², Miroslawa Nowak ³, Rachel Bruce ⁴, Sarah Cantor ⁴, Carlijn Hintzen ⁵, Philip Mease ⁶, Kendra DeBusk² and Alexis Ogdie ⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴IQVIA, New York, ⁵IQVIA, Amsterdam, Netherlands, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁷University of Pennsylvania, Philadelphia
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease resulting in significant symptom burden.1 Over time and without adequate treatment, PsA can lead to disability…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].